Erasca, Inc. (ERAS)
Largest Insider Buys in Sector
ERAS Stock Price History Chart
ERAS Stock Performance
About Erasca, Inc.
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients …
Insider Activity of Erasca, Inc.
Over the last 12 months, insiders at Erasca, Inc. have bought $181,920 and sold $0 worth of Erasca, Inc. stock.
On average, over the past 5 years, insiders at Erasca, Inc. have bought $6.78M and sold $3.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Casdin Alexander W. (director) — $181,920.
The last purchase of 80,000 shares for transaction amount of $181,920 was made by Casdin Alexander W. (director) on 2024‑05‑21.
List of Insider Buy and Sell Transactions, Erasca, Inc.
| 2024-05-21 | director | 80,000 0.0447% | $2.27 | $181,920 | +16.60% | |||
| 2023-12-06 | Chairman & CEO | 278,150 0.1825% | $1.72 | $478,418 | +27.27% | |||
| 2023-12-06 | director | 10,000 0.007% | $1.85 | $18,480 | +27.27% | |||
| 2023-12-05 | Chairman & CEO | 721,850 0.4606% | $1.69 | $1.22M | +27.22% | |||
| 2023-12-04 | director | 30,000 0.0197% | $1.66 | $49,785 | +31.75% | |||
| 2023-10-05 | Chairman & CEO | 1M 0.695% | $2.03 | $2.03M | +2.83% | |||
| 2023-06-08 | Chairman & CEO | 100,000 0.0676% | $2.75 | $275,000 | -18.38% | |||
| 2023-04-10 | director | 20,000 0.0135% | $2.76 | $55,230 | -14.44% | |||
| 2023-03-28 | Chairman & CEO | 100,000 0.0693% | $2.84 | $284,000 | -12.41% | |||
| 2023-01-10 | Chairman & CEO | 60,000 0.0413% | $3.86 | $231,420 | -29.33% | |||
| 2022-12-21 | director | 20,000 0.0162% | $4.14 | $82,800 | -35.48% | |||
| 2022-12-21 | director | 10,000 0.0091% | $4.64 | $46,400 | -35.48% | |||
| 2022-12-15 | director | 20,000 0.0167% | $4.87 | $97,490 | -42.71% | |||
| 2022-12-14 | Chairman & CEO | 40,000 0.0338% | $4.99 | $199,600 | -43.44% | |||
| 2022-12-13 | director | 307,692 0.3325% | $6.50 | $2M | -44.42% | |||
| 2021-08-10 | director | 200,000 0.2202% | $22.10 | $4.42M | -41.38% | |||
| 2021-07-26 | Sale | director | 200,000 0.2009% | $18.77 | $3.75M | -35.23% | ||
| 2021-07-20 | director | 950,000 0.7974% | $16.00 | $15.2M | -35.39% | |||
| 2021-07-20 | director | 6,200 0.0052% | $16.00 | $99,200 | -35.39% | |||
| 2021-07-20 | director | 6,000 0.005% | $16.00 | $96,000 | -35.39% |
Insider Historical Profitability
| Casdin Alexander W. | director | 573974 0.203% | $2.49 | 4 | 0 | <0.0001% |
| Lim Jonathan E | Chairman & CEO | 12899360 4.5625% | $2.49 | 7 | 0 | <0.0001% |
| Chen Bihua | director | 10813246 3.8246% | $2.49 | 3 | 1 | <0.0001% |
| Multani Pratik S | director | 172866 0.0611% | $2.49 | 1 | 0 | <0.0001% |
| Start Valerie Denise Harding | director | 20000 0.0071% | $2.49 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Arch Venture Management Llc | $22.77M | 4.65 | 11.06M | 0% | +$0 | 1.12 | |
| BlackRock | $14.38M | 2.93 | 6.98M | -4.5% | -$678,051.10 | <0.0001 | |
| Armistice Capital Llc | $12.71M | 2.59 | 6.17M | -23.77% | -$3.96M | 0.04 | |
| Artal Group S A | $9.73M | 1.98 | 4.72M | 0% | +$0 | 0.04 | |
| The Vanguard Group | $8.94M | 1.82 | 4.34M | +14.39% | +$1.12M | <0.0001 |